Smith & Nephew (LON:SN) Lowered to Sector perform Rating by Royal Bank Of Canada

Smith & Nephew (LON:SN) was downgraded by analysts at Royal Bank Of Canada to a “sector perform” rating in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. They presently have a GBX 1,350 price objective on the stock, down from their previous price objective of GBX 1,700. Royal Bank Of Canada’s target price indicates a potential upside of 11.94% from the company’s current price.

A number of other equities research analysts also recently commented on SN. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Panmure Gordon reiterated a “hold” rating and set a GBX 1,200 target price on shares of Smith & Nephew in a research note on Tuesday, December 9th. Finally, Citigroup raised their price target on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. Two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of GBX 1,381.33.

Smith & Nephew Stock Performance

SN stock opened at GBX 1,206 on Wednesday. The stock’s fifty day moving average price is GBX 1,298.60 and its 200 day moving average price is GBX 1,259.88. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The stock has a market capitalization of £13.22 billion, a price-to-earnings ratio of 43.42, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insider Activity

In other news, insider Deepak Nath sold 1,240 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total transaction of £15,586.80. 0.19% of the stock is owned by insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.